Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uveal Melanoma 2Macular Edema 2von Hippel-Lindau Disease 1Retinal Diseases 1Neoplasms 1Melanoma 1Glaucoma, Neovascular 1Conjunctival Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Ranibizumab × Clear all
NCT00089765 2017-07-02

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled

von Hippel-Lindau Disease, Macular Edema, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡